Omer Faruk Karatas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2576186/publications.pdf

Version: 2024-02-01

54 papers	1,256 citations	331259 21 h-index	377514 34 g-index
55 all docs	55 docs citations	55 times ranked	2267 citing authors

#	Article	IF	Citations
1	Low vitamin D and high cholesterol facilitate oral carcinogenesis in 4NQOâ€induced rat models via regulating glycolysis. Oral Diseases, 2023, 29, 978-989.	1.5	6
2	AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cellular Oncology (Dordrecht), 2022, 45, 41-56.	2.1	10
3	Comprehensive in silico analysis for identification of novel candidate target genes, including DHX36 , OPA1 , and SENP2 , located on chromosome 3q in head and neck cancers. Head and Neck, 2021, 43, 288-302.	0.9	3
4	Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells. Molecular Biology Reports, 2021, 48, 1393-1400.	1.0	11
5	MicroRNAâ€145 transcriptionally regulates Semaphorin 3A expression in prostate cancer cells. Cell Biology International, 2021, 45, 1082-1090.	1.4	7
6	CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer and Prostatic Diseases, 2021, 24, 891-902.	2.0	11
7	MEX3D is an oncogenic driver in prostate cancer. Prostate, 2021, 81, 1202-1213.	1.2	5
8	Synthesis and biological evaluation of 3,5â€diarylâ€pyrazole derivatives as potential antiprostate cancer agents. Archiv Der Pharmazie, 2021, 354, e2100225.	2.1	4
9	The effects of Daucus carota extract against PC3, PNT1a prostate cells, acetylcholinesterase, glutathione Sâ€transferase, and Î±â€glycosidase; an in vitroâ€“in silico study. Journal of Food Biochemistry, 2021, 45, e13975.	1.2	10
10	ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer. Cell Biology International, 2020, 44, 242-252.	1.4	11
11	Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil. Clinical Cancer Drugs, 2020, 7, 16-24.	0.3	0
12	Mode of action of carboplatin via activating p53/miRâ€145 axis in head and neck cancers. Laryngoscope, 2020, 130, 2818-2824.	1.1	9
13	Design, synthesis and biological evaluation of 3,5-diaryl isoxazole derivatives as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127427.	1.0	13
14	The roles of microRNAs in the stemness of oral cancer cells. Oral Oncology, 2020, 109, 104950.	0.8	10
15	Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells. Molecular Biology Reports, 2020, 47, 5431-5438.	1.0	8
16	Revealing the functions of novel mutations in RAB3GAP1 in Martsolf and Warburg micro syndromes. American Journal of Medical Genetics, Part A, 2019, 179, 579-587.	0.7	10
17	MicroRNAs as prognostic markers in prostate cancer. Prostate, 2019, 79, 265-271.	1.2	25
18	Could the â€œStiff Rim Signâ€•Be an Indicator of Lysyl Oxidase Activity in Breast Cancer?. Iranian Journal of Radiology, 2019, 16, .	0.1	0

#	Article	IF	Citations
19	Antiproliferative potential of miRâ€33a in laryngeal cancer Hepâ€2 cells via targeting PIM1. Head and Neck, 2018, 40, 2455-2461.	0.9	20
20	Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN. Oncotarget, 2018, 9, 14456-14471.	0.8	5
21	Characterization of stem-like cells in a new astroblastoma cell line. Experimental Cell Research, 2017, 352, 393-402.	1.2	5
22	MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications. Oral Oncology, 2017, 67, 124-130.	0.8	57
23	RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Research, 2017, 77, 4247-4257.	0.4	28
24	miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. Oncotarget, 2017, 8, 60243-60256.	0.8	34
25	Role of miR-145 in human laryngeal squamous cell carcinoma. Head and Neck, 2016, 38, 260-266.	0.9	40
26	The role of ATPâ€binding cassette transporter genes in the progression of prostate cancer. Prostate, 2016, 76, 434-444.	1.2	29
27	Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. BMC Cancer, 2016, 16, 853.	1.1	18
28	Novel mutants of the aubergine gene. Fly, 2016, 10, 81-90.	0.9	16
29	The altered promoter methylation of oxytocin receptor gene in autism. Journal of Neurogenetics, 2016, 30, 280-284.	0.6	48
30	Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. Cellular Oncology (Dordrecht), 2016, 39, 187-193.	2.1	75
31	The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells. Tumor Biology, 2016, 37, 4183-4192.	0.8	33
32	MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope, 2015, 125, E377-E381.	1.1	27
33	Differential Expression of Hypertension-Associated MicroRNAs in the Plasma of Patients With White Coat Hypertension. Medicine (United States), 2015, 94, e693.	0.4	50
34	Overexpression of miR-145â€“5p Inhibits Proliferation of Prostate Cancer Cells and Reduces SOX2 Expression. Cancer Investigation, 2015, 33, 251-258.	0.6	73
35	Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clinical and Experimental Hypertension, 2015, 37, 643-649.	0.5	69
36	NovelPOC1Amutation in primordial dwarfism reveals new insights for centriole biogenesis. Human Molecular Genetics, 2015, 24, 5378-5387.	1.4	26

#	Article	IF	Citations
37	Whole-exome sequencing revealed two novel mutations in Usher syndrome. Gene, 2015, 563, 215-218.	1.0	6
38	Alpha-B-crystallin expression in human laryngeal squamous cell carcinoma tissues. Head and Neck, 2015, 37, 1344-1348.	0.9	20
39	Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. International Journal of Cancer, 2015, 136, 875-879.	2.3	42
40	Interlocked loops trigger lineage specification and stable fates in the Drosophila nervous system. Nature Communications, 2014, 5, 4484.	5.8	16
41	Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate, 2014, 74, 1498-1505.	1.2	46
42	Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. Journal of Gene Medicine, 2014, 16, 331-335.	1.4	72
43	The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncology, 2014, 10, 1027-1048.	1.1	57
44	A novel frameshift mutation and infrequent clinical findings in two cases with Dyggveâ€“Melchiorâ€“Clausen syndrome. Clinical Dysmorphology, 2014, 23, 1-7.	0.1	5
45	miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer. PLoS ONE, 2014, 9, e98675.	1.1	70
46	Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens. Current Stem Cell Research and Therapy, 2014, 9, 347-353.	0.6	18
47	A novel EFNB1 mutation in a patient with craniofrontonasal syndrome and right hallux duplication. Gene, 2013, 527, 675-678.	1.0	5
48	MicroRNA profiling in lymphocytes and serum of tyrosinemia type-I patients. Molecular Biology Reports, 2013, 40, 4619-4623.	1.0	5
49	Gcm/Glide-dependent conversion into glia depends on neural stem cell age, but not on division, triggering a chromatin signature that is conserved in vertebrate glia. Development (Cambridge), 2011, 138, 4167-4178.	1.2	22
50	Toward PCR-free mutation detection based on surface-enhanced Raman scattering. Proceedings of SPIE, 2009, , .	0.8	0
51	Interaction of gold nanoparticles with mitochondria. Colloids and Surfaces B: Biointerfaces, 2009, 71, 315-318.	2.5	65
52	MiR-33a and statins collaboratively reduce the proliferative capacity of prostate cancer cells. The European Research Journal, 0, , .	0.1	1
53	Perisentrik inv(12)(p11.2q14)â€™nin Ä°nfertilite ve Tekrarlayan DÃ¼ÅŸÃ¼klerle Ä°liÅŸkisi: Vaka Ã–rneÄŸi ve LiteratÃ¼r TaramasÄ±. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 0, , .	0.3	0
54	The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells. The European Research Journal, 0, , .	0.1	0